Childhood hypophosphatasia

From WikiMD's WELLNESSPEDIA

Other Names: Childhood-onset hypophosphatasia; Childhood-onset phosphoethanolaminuria; Childhood-onset Rathburn disease

Childhood hypophosphatasia is a form of hypophosphatasia, a rare condition that affects the bones.

Onset[edit]

Childhood hypophosphatasia, specifically, is generally diagnosed when the condition develops after six months of age but before adulthood.

Cause[edit]

Childhood hypophosphatasia is caused by changes (mutations) in the ALPL gene.

Inheritance[edit]

It can be inherited in an autosomal dominant or autosomal recessive manner.

Signs and symptoms[edit]

Signs and symptoms vary but may include delayed motor milestones; low bone mineral density for age; early loss of baby teeth (before age 5); bone and joint pain; short stature; a waddling gait; skeletal malformations; and/or unexplained broken bones. The forms of hypophosphatasia that develop during childhood are generally more mild than those that appear in infancy.

Diagnosis[edit]

The clinical variability of HPP is considerable, with the majority of findings in HPP relating either directly or indirectly to effects of TNSALP dysfunction in bone . Patients with perinatal or infantile HPP frequently manifest with severe deficit in bone mineralization, resulting in small thorax, pulmonary hypoplasia, and severe bowing of the limbs. Patients with childhood hypophosphatasia typically lack these life-threatening signs, but may still have significant disease, with poor mobility, chronic pain, and short stature . These same patients may also have significant rickets, long bone deformity, and non-traumatic fractures . Fractures which occur in patients with HPP may heal poorly and can reoccur.

Treatment[edit]

Treatment is supportive and based on the signs and symptoms present in each person. Recently an enzyme replacement therapy (ERT) called asfotase alfa has been show to improve bone symptoms in people with childhood hypophosphatasia and has been approved by the FDA.

NIH genetic and rare disease info[edit]

Childhood hypophosphatasia is a rare disease.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.